Full Press Release Details
Therapeutics Announces Proposed Public Offering
and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to
transform cancer care, today announced that it intends to offer to sell common shares and warrants in an underwritten public offering.
All of the common shares and warrants are to be sold by the Company. The offering is subject to market conditions and there can be no
assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
is acting as the sole book-running manager for the offering.
Company intends to use the net proceeds from the offering primarily for working capital requirements, general corporate purposes, and
the advancement of business objectives.
securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus,
filed with the U.S. Securities and Exchange Commission (the "SEC") on January 22, 2024 and declared effective on January
31, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus
describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity,
17 State Street, 41 st Floor, New York, New York 10004. Before investing in this offering, interested parties should read
in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has
filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which
provide more information about the Company and such offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction.
BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information
is available at https://briacell.com/ .
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements, including those related to our ability to close the underwritten public offering
and the use of proceeds, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions
that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not
prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risk Factors" in
the Company's most recent annual report, and in the Company's other filings with the Canadian securities regulatory authorities
and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca
and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics
Corp. undertakes no duty to update such information except as required under applicable law.
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
William V. Williams, MD